We hear claims of retail investors cannot value revenue biotechs
What about the institutional investors and all professional investors in the placement who received shares at 40c
Why was placement at 40c after all this progress ?
dyor outside of HC is critical
Dr Dunn, page-92
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)